Vanguards of Health Care: Akasa Tackles Revenue-Cycle Complexity

AKASA is leveraging advanced AI, including large language models (LLMs), to streamline the complex revenue cycle management within the U.S. healthcare system, as detailed by CEO Malinka Walaliyadde on Bloomberg Intelligence. The company emphasizes that its custom AI models, tailored for specific health systems, significantly outperform generic solutions in processing patient records. Operating on a performance-based business model, AKASA aims to enhance real-time payer-provider communication, addressing the systemic inefficiencies inherent in America's overlapping healthcare payment structures.

Analysis

AKASA is positioning itself as a key disruptor in the U.S. healthcare revenue cycle management (RCM) sector by applying advanced, custom-built artificial intelligence. According to CEO Malinka Walaliyadde, the company directly addresses the systemic inefficiencies created by America's complex and overlapping payment models. The core of AKASA's strategy lies in its use of proprietary AI, including large language models (LLMs) capable of processing extensive patient records in minutes, which it claims significantly outperforms generic, off-the-shelf AI solutions. This technological differentiation is coupled with a performance-based business model, which aligns AKASA's incentives with those of its health system clients and lowers the barrier to adoption. While the company is private and thus has a low direct market impact, its approach signals a significant technological shift within the healthcare administration space, challenging incumbent RCM providers with a more efficient and technologically advanced solution aimed at enabling real-time payer-provider communication.

Key Decisions for Investors

• Investors with positions in incumbent public RCM companies should monitor the competitive threat from AI-native firms like AKASA, whose performance-based pricing and custom-model approach could erode traditional market share.
• For those seeking exposure to healthcare AI, AKASA represents a key archetype of a high-growth, private company to watch for future funding rounds, a potential IPO, or as an acquisition target by larger health-tech players.
• When conducting due diligence on any company in the RCM or healthcare AI space, the distinction between using generic versus custom-built AI and the adoption of a performance-based business model are critical factors to evaluate a company's competitive moat and value proposition.